Investigation Report on China’s Emtricitabine/Tenofovir Market 2021-2025

$2,600$3,900

The sales value of Emtricitabine/Tenofovir in the Chinese market reached CNY16.43 million in 2020 and the CAGR is 35.4% from 2016 to 2020, which is a very high level.

Clear

Description

Emtricitabine/Tenofovir is the first HIV drug approved for prophylaxis. It was developed by Gilead Sciences Inc (the original drug is called TRUVADA). Its product was first approved in the United States in 2004 and was launched in China in 2012. TRUVAD was covered by China’s national drug reimbursement list (NDRL) in 2017. As of the end of 2020, the manufacturers in the Chinese Emtricitabine/Tenofovir market are Gilead Sciences Inc and Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

According to CRI’s market research, the sales value of Emtricitabine/Tenofovir in the Chinese market has increased year by year from 2016 to 2019, with a decline in 2020. The main reason for this decline is that the COVID-19 epidemic has affected the overall diagnosis and treatment business of the hospital. At the beginning of 2017, Emtricitabine/Tenofovir was included in China’s Medical Insurance, so its sales value grew rapidly to CNY10.86 million in 2018, with an annual growth rate of 103%. The sales value of Emtricitabine/Tenofovir in the Chinese market reached CNY16.43 million in 2020 and the CAGR is 35.4% from 2016 to 2020, which is a very high level.

CRI predicts that with the increase in the number of AIDS patients in China, the sales of Emtricitabine/Tenofovir will also increase from 2016 to 2019. In 2019, the number of surviving HIV infections in China reached 958,000. In 2020, the number of surviving AIDS infections in China increased to 1.045 million, with an increase of 9%. The number of new infections will still show an increasing trend in the future. How to prevent new HIV infections has become the key to prevent and control the spread of AIDS. Therefore, sales in Emtricitabine/Tenofovir of the preventive HIV drugs will continue to increase. By 2020, 2 companies have launched generic versions of Truvada (Emtricitabine/Tenofovir) in China. The generic version from Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the first Chinese-made HIV combination tablet in the country. Qilu Pharmaceutical and Hisco Pharmaceutical are waiting for an Abbreviated New Drug Application (ANDA) approval for their generic version, and they will compete for the market after approval. The market competition of Emtricitabine/Tenofovir in China will become more intense. Sales prices are expected to continue to fall, and sales volume will increase accordingly. In addition, the effective alleviation of the COVID-19 epidemic during the period of 2021-2025 will also enable the sales of Emtricitabine/Tenofovir to have restorative growth.

Topics Covered:
-The impact of COVID-19 on China’s Emtricitabine/Tenofovir market
– Sales value of China’s Emtricitabine/Tenofovir 2016-2020
– Competitive landscape of China’s Emtricitabine/Tenofovir market
– Prices of Emtricitabine/Tenofovir in China
– Prices of Emtricitabine/Tenofovir in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Emtricitabine/Tenofovir market
– Prospect of China’s Emtricitabine/Tenofovir market from 2021 to 2025

Additional information

Publisher

Date Published

Pages

Charts

Format

Table of Contents

1 Relevant Concepts of Emtricitabine/Tenofovir
1.1 Indications for Emtricitabine/Tenofovir
1.2 Development of Emtricitabine/Tenofovir in China
1.3 Governmental Approval of Emtricitabine/Tenofovir in China
1.4 The Impact of COVID-19 on Emtricitabine/Tenofovir sales in China

2 Sales of Emtricitabine/Tenofovir in China, 2016-2020
2.1 Sales Value of Emtricitabine/Tenofovir
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Emtricitabine/Tenofovir
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Emtricitabine/Tenofovir by Dosage Form in China, 2016-2020
2.3.1 Tablets
2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Emtricitabine/Tenofovir Manufacturers in China, 2016-2020
3.1 Analysis of Market Share of Major Emtricitabine/Tenofovir Manufacturers
3.1.1 Investigation on Market Share by Sales Value
3.1.2 Investigation on Market Share by Sales volume
3.2 Gilead Sciences Inc
3.2.1 Enterprise Profile
3.2.2 Sales of TRUVADA (Gilead Sciences Inc’s Emtricitabine/Tenofovir) in China
3.3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of Clyke (Chia Tai Tianqing Pharmaceutical Group Co., Ltd.’s Emtricitabine/Tenofovir) in China

4 Prices of Emtricitabine/Tenofovir for Different Manufacturers in China, 2020-2021
4.1 Gilead Sciences Inc (TRUVADA)
4.2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Clyke)

5 Prospect of Chinese Emtricitabine/Tenofovir drug Market, 2021-2025
5.1 Influential Factors of Chinese Emtricitabine/Tenofovir Market Development
5.1.1 The Impact of COVID-19 on Chinese Emtricitabine/Tenofovir Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend

List of Charts
Chart Patent Information About Emtricitabine/Tenofovir Tablets Registration in China
Chart Sales Value of Emtricitabine/Tenofovir Tablets over the World
Chart Sales Value of Emtricitabine/Tenofovir Tablets in China, 2016-2020
Chart Sales Value of Emtricitabine/Tenofovir Tablets in China by Region, 2016-2020
Chart Sales Volume of Emtricitabine/Tenofovir Tablets in China, 2016-2020
Chart Sales Volume of Emtricitabine/Tenofovir Tablets in China by Region, 2016-2020
Chart Market Share by Sales Value of Top Emtricitabine/Tenofovir Manufacturers in China, 2016-2020
Chart Sales Value and Volume of TRUVADA in China, 2016-2020
Chart Sales Value and Volume of Clyke in China, 2016-2020
Chart Referential Prices of TRUVADA in China, 2020-2021
Chart Referential Prices of Clyke in China, 2020-2021
Chart Forecast on Sales Value of Emtricitabine/Tenofovir in China, 2021-2025
Chart Forecast on Sales Volume of Emtricitabine/Tenofovir in China, 2021-2025